GB Patent

GB2203831A — Diagnosis of malignant tumours by fluorescence

Assigned to Academy of Applied Science Inc · Expires 1988-10-26 · 38y expired

What this patent protects

In a non-invasive apparatus for the diagnosis of malignant tumours by intrinsic fluorescence UV light from a source 1 is transmitted by quartz optic fibres 2 to the surface of the living tissue 3, stimulating its intrinsic fluorescence which is transmitted by ordinary optic fibre…

USPTO Abstract

In a non-invasive apparatus for the diagnosis of malignant tumours by intrinsic fluorescence UV light from a source 1 is transmitted by quartz optic fibres 2 to the surface of the living tissue 3, stimulating its intrinsic fluorescence which is transmitted by ordinary optic fibres 4 for signal processing and subsequent display of the intrinsic fluorescence spectrum by graphical means. The presence of the characteristic wave peak in the graph corresponding to evidence of malignancy permits appropriate diagnosis. The colour of the intrinsic fluorescence of the living tissue which determines the presence or absence of malignancy, may also be made with the naked eye. The apparatus may be used clinically to diagnose body surface malignant tumours, as well as those in body cavities within the reach of the optic fibres. <IMAGE>

Drugs covered by this patent

Patent Metadata

Patent number
GB2203831A
Jurisdiction
GB
Classification
Expires
1988-10-26
Drug substance claim
No
Drug product claim
No
Assignee
Academy of Applied Science Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.